利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

47 条记录 (耗时 0.031 秒)

    Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
    1.
    发明申请
    Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods 审中-公开
    含有视网膜友好赋形剂的治疗眼用组合物及相关方法

    公开(公告)号：US20050250737A1

    公开(公告)日：2005-11-10

    申请号：US11091977

    申请日：2005-03-28

    申请人： Patrick Hughes ,  Laurent Delahaye ,  Michele Boix ,  James Chang ,  Robert Lyons

    发明人： Patrick Hughes ,  Laurent Delahaye ,  Michele Boix ,  James Chang ,  Robert Lyons

    IPC分类号： A61K9/00 ,  A61K31/573 ,  A61K31/724 ,  A61K47/36

    CPC分类号： A61K9/0048 ,  A61K31/573 ,  A61K47/36 ,  A61K47/40

    摘要： Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described.

    摘要翻译： 描述适于施用于人或动物的眼睛内部的药物组合物。 本发明组合物包括一种或多种有效提供相对于现有眼内眼用组合物的毒性降低的成分。 本发明的组合物包含一种或多种治疗剂，其用量在置于眼中时可提供所需的治疗效果，以及一种或多种视黄醛友好的赋形剂，其相对于苯甲醇或聚山梨酸酯80具有降低的毒性。在某些组合物中，赋形剂 组合物的组分包含一种或多种环糊精或环糊精衍生物。 还描述了使用组合物治疗眼睛病症的方法。

    Sustained release intraocular drug delivery systems
    2.
    发明申请
    Sustained release intraocular drug delivery systems 审中-公开
    持续释放眼内药物递送系统

    公开(公告)号：US20060182783A1

    公开(公告)日：2006-08-17

    申请号：US11370301

    申请日：2006-03-08

    申请人： Patrick Hughes ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Robert Lyons

    发明人： Patrick Hughes ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Robert Lyons

    IPC分类号： A61K48/00 ,  A61F2/00

    CPC分类号： A61K9/0051 ,  A61F9/0008 ,  A61F9/0017 ,  A61K9/1647 ,  A61K31/724 ,  A61K47/34 ,  A61K47/40 ,  A61K48/0041

    摘要： Biocompatible intraocular drug delivery systems include a anti-angiogenic macromolecular therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent contains a component selected from the group consisting of anti-angiogenesis peptides and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

    摘要翻译： 生物相容性眼内药物递送系统包括抗血管生成大分子治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可以保持其三维结构，或者治疗剂可以具有改变的三维结构，但保持其治疗活性。 治疗剂含有选自抗血管生成肽和核酸试剂的组分。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。

    Triamcinolone compositions for intravitreal administration to treat ocular conditions
    3.
    发明申请
    Triamcinolone compositions for intravitreal administration to treat ocular conditions 审中-公开
    用于玻璃体内给药以治疗眼部病症的曲安奈德组合物

    公开(公告)号：US20060141049A1

    公开(公告)日：2006-06-29

    申请号：US11354415

    申请日：2006-02-14

    申请人： Robert Lyons ,  James Chang ,  John Trogden ,  Scott Whitcup

    发明人： Robert Lyons ,  James Chang ,  John Trogden ,  Scott Whitcup

    IPC分类号： A61K31/728 ,  A61K31/695 ,  A61K9/14

    CPC分类号： A61K9/0048 ,  A61K31/56 ,  A61K31/573 ,  A61K47/36

    摘要： Triamcinolone compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.

    摘要翻译： 提供曲安奈德组合物，以及使用这些组合物的方法，其用于注射到人眼的玻璃体中。 这样的组合物可以包括以治疗有效量存在的曲安奈德颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约80,000cps至约300,000cps的范围内。 组合物有利地将曲安奈德颗粒悬浮较长时间。

    Inhibition of irritating side effects associated with use of a topical ophthalmic medication
    4.
    发明申请
    Inhibition of irritating side effects associated with use of a topical ophthalmic medication 失效

    公开(公告)号：US20050004074A1

    公开(公告)日：2005-01-06

    申请号：US10613097

    申请日：2003-07-01

    申请人： Robert Lyons ,  James Chang

    发明人： Robert Lyons ,  James Chang

    IPC分类号： A61K9/00 ,  A61K31/557 ,  A61K31/724

    CPC分类号： A61K9/0048 ,  A61K31/557 ,  A61K31/724

    摘要： This invention relates to a method of reducing an irritating or adverse side effect associated with the topical use of an active ophthalmic drug comprising incorporating an effective amount of a cyclodextrin or cyclodextrin derivative into a formulation to complex the active drug such that the concentration of the free active drug is reduced below a tolerable threshold, and incorporating an effective amount of a viscosity increasing agent in said formulation such that the bioavailability of said drug is high enough to be therapeutically effective, wherein the cyclodextrin or cyclodextrin derivative is not required to solubilize the active drug. Another aspect of this invention relates to topical ophthalmic formulations comprising an active drug, a cyclodextrin or cyclodextrin derivative, and a viscosity-enhancing agent, in effective amounts as stated above.

    LOW IMMUNOGENICITY CORTICOSTEROID COMPOSITIONS
    5.
    发明申请
    LOW IMMUNOGENICITY CORTICOSTEROID COMPOSITIONS 审中-公开
    低免疫球蛋白组合物

    公开(公告)号：US20070224278A1

    公开(公告)日：2007-09-27

    申请号：US11741366

    申请日：2007-04-27

    申请人： Robert Lyons ,  Michael Robinson ,  James Chang ,  Sam Lam ,  John Trogden ,  Scott Whitcup

    发明人： Robert Lyons ,  Michael Robinson ,  James Chang ,  Sam Lam ,  John Trogden ,  Scott Whitcup

    IPC分类号： A61K9/14 ,  A61K31/56

    CPC分类号： A61K9/0019 ,  A61K9/0048 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61K31/715 ,  A61K47/02 ,  A61K47/34 ,  A61K47/36 ,  A61K47/40

    摘要： Triamcinolone compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes or into a joint are provided. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps t a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.

    摘要翻译： 提供了曲安奈德组合物，以及使用这种组合物的方法，其可用于注射到人眼玻璃体或关节中。 这样的组合物可以包括以治疗有效量存在的曲安奈德颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约80,000cps至约300,000cps的范围内。 在最优选的实施方案中，在25℃下，粘度为约140,000cps至约280,000cps，剪切速率为0.1 /秒。组合物有利地将曲安奈德颗粒悬浮较长时间。

    Ophthalmic visualization compositions and methods of using same
    6.
    发明申请
    Ophthalmic visualization compositions and methods of using same 审中-公开
    眼科可视化组合物及其使用方法

    公开(公告)号：US20070218007A1

    公开(公告)日：2007-09-20

    申请号：US11378506

    申请日：2006-03-17

    申请人： James Chang ,  Robert Lyons

    发明人： James Chang ,  Robert Lyons

    IPC分类号： A61K49/00

    CPC分类号： A61K9/10 ,  A61K9/0048 ,  A61K9/107 ,  A61K47/26 ,  A61K47/38 ,  A61K47/44 ,  A61K49/0041 ,  A61K49/0043 ,  A61K49/0071

    摘要： Compositions and methods useful for at least assisting in visualizing vitreous bodies of eyes of humans or animals are provided. Such compositions include a contrast component and a carrier component and are substantially free of any therapeutic agent effective to have pharmacological activity in an eye in which the composition is placed. Methods of using such compositions as visualization devices are also provided.

    摘要翻译： 提供了用于至少辅助人类或动物的眼睛的玻璃体视觉化的组合物和方法。 这样的组合物包括造影剂组分和载体组分，并且基本上没有任何有效地在其中放置组合物的眼睛中具有药理活性的治疗剂。 还提供了使用这些组合物作为可视化装置的方法。

    Compositions and methods for treating a posterior segment of an eye
    9.
    发明申请
    Compositions and methods for treating a posterior segment of an eye 审中-公开
    用于治疗眼后段的组合物和方法

    公开(公告)号：US20050101582A1

    公开(公告)日：2005-05-12

    申请号：US10966764

    申请日：2004-10-14

    申请人： Robert Lyons ,  James Chang ,  John Trogden ,  Scott Whitcup

    发明人： Robert Lyons ,  James Chang ,  John Trogden ,  Scott Whitcup

    IPC分类号： A61K9/00 ,  A61K31/573 ,  A61K47/36

    CPC分类号： A61K31/58 ,  A61K9/0048 ,  A61K31/573 ,  A61K47/36

    摘要： Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.

    摘要翻译： 提供了组合物和使用这种组合物的方法，其可用于注射到人或动物眼睛的后段中。 这样的组合物包括以治疗有效量存在的含皮质类固醇成分的颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约140,000cps至约300,000cps的范围内。 组合物有利地将颗粒悬浮长时间。